InvestSMART

Biome Australia Limited (ASX:BIO)

ALERT: Price-sensitive ASX Announcement for BIO
Current share price for BIO : $0.285 -0.195 (-40.63%)+
Announcement
Release
3 Feb 2026 8:17AM
Price at Release
$0.480
Full Release
download
Summary
Biome Australia Limited announced that it has received ethics approval from the La Trobe University Human Research Ethics Committee to commence its first human clinical trial on its proprietary probiotic strain, Lactobacillus plantarum BMB18. This trial will be a randomised, double-blind, placebo-controlled study involving 240 participants to evaluate the efficacy of BMB18 on digestive symptoms and mood disturbances. It aims to explore the potential of the strain in new product development within Biome's Activated Probiotics and Activated Therapeutics ranges. The study aligns with Biome's strategic plan and represents an important asset due to its proprietary nature and potential for IP protection, which could offer the company a significant competitive advantage.
Key Points
  • Ethics approval granted for BMB18 human clinical trial.
  • Trial to recruit 240 participants with digestive symptoms and mood disturbances.
  • Randomised, double-blind, placebo-controlled trial design.
  • Study explores efficacy of Lactobacillus plantarum BMB18.
  • BMB18 is wholly owned by Biome, enhancing IP protection.
  • Trial aligns with Biome's Vision 27 strategic plan.
  • Potential new product development opportunities in Activated Probiotics and Activated Therapeutics.
  • Collaborative research partnership with La Trobe University.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.